Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 12:13 pm Sale | 2024-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | EVENTIDE ASSET MANAGEMENT LLC | 4,475,054 6.280% | -2,615,054 (-36.88%) | Filing History |
| 2025-02-04 4:06 pm Purchase | 2025-01-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Millennium Management LLC | 3,781,298 5.300% | 3,781,298 (New Position) | Filing History |
| 2025-01-31 12:44 pm Purchase | 2025-01-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Walters William T | 7,050,000 9.900% | 550,000 (+8.46%) | Filing History |
| 2025-01-31 10:09 am Sale | 2024-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | VANGUARD GROUP INC | 3,271,240 4.590% | -1,341,467 (-29.08%) | Filing History |
| 2025-01-22 10:08 am Purchase | 2025-01-21 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Walters William T | 6,500,000 9.100% | 1,500,000 (+30.00%) | Filing History |
| 2025-01-08 6:49 pm Purchase | 2025-01-08 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Walters William T | 5,000,000 7.000% | 1,000,000 (+25.00%) | Filing History |
| 2024-12-10 12:42 pm Purchase | 2024-12-03 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Walters William T | 4,000,000 5.600% | 4,000,000 (New Position) | Filing History |
| 2024-12-06 11:44 am Sale | 2024-11-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | FMR LLC | 175,863 0.200% | -4,899,974 (-96.54%) | Filing History |
| 2024-11-14 4:20 pm Sale | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 2,737,221 3.900% | -1,001,261 (-26.78%) | Filing History |
| 2024-11-12 6:00 pm Unchanged | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | VANGUARD GROUP INC | 4,612,707 6.480% | 0 (Unchanged) | Filing History |
| 2024-11-06 2:47 pm Sale | 2024-10-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | EVENTIDE ASSET MANAGEMENT LLC | 7,090,108 9.970% | -4,469,867 (-38.67%) | Filing History |
| 2024-11-04 2:16 pm Sale | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | VANGUARD GROUP INC | 4,612,707 6.480% | -737,751 (-13.79%) | Filing History |
| 2024-10-18 12:50 pm Sale | 2024-09-30 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | STATE STREET CORP STT | 1,246,613 1.800% | -3,170,443 (-71.78%) | Filing History |
| 2024-10-07 11:37 am Sale | 2024-10-04 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | FMR LLC | 5,075,837 7.138% | -5,261,134 (-50.90%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 3,738,482 5.300% | -101,347 (-2.64%) | Filing History |
| 2024-02-13 7:43 pm Sale | 2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Avidity Partners Management LP | 0 0.000% | -5,150,000 (Position Closed) | Filing History |
| 2024-02-13 5:17 pm Purchase | 2023-12-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | VANGUARD GROUP INC | 5,350,458 7.560% | 1,190,309 (+28.61%) | Filing History |
| 2024-02-09 6:05 pm Sale | 2024-02-07 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Capital International Investors | 2,819,664 4.000% | -228,518 (-7.50%) | Filing History |
| 2024-02-09 10:05 am Purchase | 2024-02-08 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | FMR LLC | 10,336,971 14.607% | 2,427,795 (+30.70%) | Filing History |
| 2024-02-09 08:40 am Sale | 2023-12-29 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | WELLINGTON MANAGEMENT GROUP LLP | 68,791 0.100% | -3,549,702 (-98.10%) | Filing History |